Loading quotes...
Forecast
The analysts' average price target is €30.65 (+136.68%). The median is €30.93 (+138.84%).
| Buy |
18 |
| Hold |
1 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Nurix: Roche deal strengthens outlook for BTK degrader bexobrutideg
At the H.C. Wainwright conference Nurix highlighted the shift from platform research to late-stage development and emphasized strong phase I data for bexobrutideg with response rates of 80–90%. The partnership with Roche, signed in June, includes a $700 million upfront payment and up to $2.3 billion in milestones plus a 50/50 profit split in the U.S.; Roche will take over development and commercialization outside the U.S. Two registration-relevant trials are already underway (100 patients in late-line CLL, a 620-patient comparative study versus pirtobrutinib), while Nurix continues to expand its platform through collaborations with Sanofi, Gilead and Pfizer. » More on de.investing.com
Nurix Therapeutics highlights bexobrutideg progress and major Roche partnership
At the Wells Fargo conference, Nurix presented clinical progress of its BTK degrader bexobrutideg, reporting an 83% response rate and a median progression-free survival of 22.1 months in heavily pretreated CLL, and plans a phase III study versus pirtobrutinib. The 2024 collaboration with Roche includes a $700 million upfront payment and up to $2.3 billion in milestones; development costs will be split 40/60. The company is also advancing immunology programs for CSU and MS, expanding partnerships (Sanofi, Gilead, Pfizer), and sees future commercialization as contingent on demonstrating safety, selectivity, and durable efficacy. » More on de.investing.com
Nurix Therapeutics reaches 52-week high at $26.40
Nurix Therapeutics' stock rose to a 52-week high of $26.40 and posted a one-year total return of 159% with a market capitalization of $2.72 billion; according to InvestingPro the stock is trading near its fair value. Analysts raised price targets after the Q2 report and the collaboration agreement with Roche (Mizuho, Truist, Baird, Morgan Stanley) and maintained positive ratings. InvestingPro predicts a return to profitability this year with an expected EPS of $3.80. » More on de.investing.com
Nurix Therapeutics reaches 52-week high at $25.22
Nurix Therapeutics' stock closed at $25.22, reaching a 52-week high, supported by a year-to-date gain of around 140.5% and a six-month increase of about 55%. Analysts raised several price targets and maintained mostly positive ratings following the Q2 2026 earnings report and the collaboration agreement with Roche on Bexdeg. A fair-value analysis by InvestingPro currently rates the stock as slightly overvalued, placing it on the watchlist for significantly overvalued names. » More on de.investing.com
Nurix starts global phase-3 study DAYBreak CLL-306 for bexobrutideg
Nurix has enrolled the first patient in the global, randomized phase-3 study DAYBreak CLL-306, which is evaluating bexobrutideg in patients with relapsed or refractory CLL/SLL after treatment with covalent BTK inhibitors. About 620 patients will be randomized 1:1 to receive either 600 mg bexobrutideg orally once daily or pirtobrutinib. Primary endpoints are objective response rate and progression-free survival, assessed by an independent review committee. The study is being conducted in collaboration with Roche and aims to demonstrate potential superiority of BTK degradation versus non-covalent inhibition and to support regulatory submissions worldwide. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | August 2026 | YoY |
|---|---|---|
| Revenue | 579.36m | 8,479.88% |
| Gross profit | 577.52m | 23,229.07% |
| Net profit | 473.26m | 740.20% |
| EBITDA | 486.82m | 798.97% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.42bn |
Number of shares | 109.25m |
52-week high/low | €25.68 - €11.31 |
| Dividends | No |
Beta | 1.80 |
P/E ratio | 5.68 |
PEG ratio | 0.04 |
P/B ratio | 1.64 |
P/S ratio | 2.22 |
Company profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
| Name | NURIX THERAP. DL-,001 |
| CEO | Arthur T. Sands |
| Headquarters | Brisbane,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 24/07/2020 |
| Employees | 317 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | NRIX |